Navigation Links
AMRI Strengthens Business Development and Marketing Groups
Date:4/24/2012

ALBANY, N.Y., April 24, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today key changes in its Business Development and Marketing functions.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

AMRI's separate North American Discovery and Development teams are being combined into one functional sales organization, under the leadership of Christopher Conway, who has been promoted to Vice President, Business Development, North America. This creates a seamless integration of business development and marketing efforts in North America with the goal of optimizing territory cross-selling opportunities and customer service. 

Mr. Conway joined AMRI in 2008 as a Sales Manager on AMRI's U.S. discovery team.  He was promoted to Senior Director of the North America Discovery market in late 2010.  In addition to his contributions in the closing of multi-year contracts for AMRI with large pharmaceutical, biotech, non-profit, academic and government organizations, Chris also led the development of AMRI's insourcing strategy, a new model to support drug discovery and development for pharmaceutical and biotechnology companies within their own facilities. Prior to joining AMRI, Chris held sales and leadership positions of increasing responsibility at Johnson and Johnson and completed J&J's Sales Leadership Development Program.  During his tenure at Johnson & Johnson, Chris received awards including J&J's Global Standards of Leadership Award and Ortho-McNeil Neurologic's National Innovation Award. Chris also sits on the American Cancer Society Corporate Council.

In a separate organizational change, Louis Garguilo has been promoted to Vice President, Business Development. In addition to his responsibility for AMRI's business development activity in the Japan/Asia Pacific markets, Mr. Garguilo has assumed responsibility for AMRI's marketing communications activities. In Mr. Garguilo's expanded role, he will continue to lead AMRI's sales efforts in the Japan/Asia Pacific markets while overseeing marketing communications activities as AMRI rolls out its rebranding campaign. Louis has prior training and experience in international marketing and communications, and has been leading these efforts already for his territories. This expanded role allows Louis to oversee marketing activities for AMRI on a global basis.

Mr. Garguilo's expertise in Japanese culture and business came from 16 years living in Japan, teaching English as a second language and advising U.S. corporations in the fields of Japanese communications and culture. Upon returning to the United States, Louis worked for New York State as Director of Industry Development for various high-tech industries, including pharmaceuticals and biotechnology. He also served as Chief Strategic Officer at KnowledgeXtensions, Inc. Louis also established and managed a Japan/U.S. consulting company specializing in strategic communications, marketing and business development initiatives. Louis joined AMRI in 2006.

In a third move to enhance marketing efforts, AMRI has hired Notch Communications, which will be working with AMRI on executing its marketing strategy, including a re-branding campaign and enhanced media outreach. Based in the U.K., the principals at Notch have a long history and track record supporting the CRO/CMO industry and have contributed significantly in the past to several industry leading organizations.

AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D., said, "The promotions and changes in responsibility announced today recognize the achievements and leadership contributions of Mr. Conway and Mr. Garguilo and are designed to lead to a tighter integration and enhanced performance of our sales teams. In addition, the increased investment in our marketing activities through the relationship with Notch, led by Mr. Garguilo, will support our efforts at greater brand awareness on a global scale and should provide us with greater reach and access to existing and new customers. As the industry we serve continues to seek innovative new strategies for R&D efficiency and productivity, AMRI will be launching a new marketing campaign to ensure our customers understand how AMRI is differentiated in the marketplace and the full value we can provide them. I would like to congratulate Mr. Conway and Mr. Garguilo on their promotions. We look forward to comprehensively engaging our customers and serving their drug discovery, development, and manufacturing needs."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING(TM), a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information, please visit www.amriglobal.com.


'/>"/>
SOURCE AMRI
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
2. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
3. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
4. Fate Therapeutics Strengthens Its iPSC Platform
5. ZyGEM Strengthens Senior Management Team With New Appointments
6. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
7. AMTs EGM Passes All Resolutions and Strengthens Supervisory Board With Joseph Feczko, Steven Holtzman and Francois Meyer
8. Titanium coating with protein flower bouquet nanoclusters strengthens implant attachment
9. Dyadic International Strengthens Management Team
10. ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan
11. SIRO Clinpharm Strengthens its Clinical Trials Supplies Service Offering in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017 Shareholder rights law firm ... whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... connection with the proposed sale of the Company to ... that develops small molecules for the acute treatment of ... it had signed a definitive merger agreement with Eli ...
(Date:1/18/2017)...  Market Research Future published a half-cooked research report on Global ... at a CAGR of 12% during the period 2016 to 2022. ... ... cell division without any control. These abnormal cells have the ability ... cells can spread to other parts of the body through the ...
(Date:1/17/2017)...  An international team of researchers from UC ... Hospital Albrechtsen Research Centre/University of Manitoba have identified ... need affecting nearly one in 15 Americans. Published ... results identify small molecule drugs with neuroprotective and ... in animal models of metabolic, chemical and infection ...
(Date:1/17/2017)... , Jan. 17, 2017 Noom ... is the first to offer fully Spanish behavior ... Noom,s Spanish diabetes prevention and healthy ... and accessibility of lifestyle interventions among Hispanic Americans ... conditions. Noom,s robust food database, program-specific curriculum content ...
Breaking Biology Technology:
(Date:12/7/2016)... BioCatch , the global leader in behavioral ... which grew to over 40 granted and pending patents. ... , , The Company,s ... " System, Device, and Method Estimating Force Applied to a Touch ... forego costly hardware components needed to estimate the force and pressure applied ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
Breaking Biology News(10 mins):